How we manage persons with hereditary angioedema

British Journal of Haematology

Volumn 173, Issue 6, 2016, Pages 831-843

  Zuraw, Bruce L ^a,b   Christiansen, Sandra C ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b VA SAN DIEGO HEALTHCARE SYSTEM   (United States)

Author keywords

bradykinin; C1 inhibitor; Hereditary angioedema; Management; treatment

Indexed keywords

COMPLEMENT COMPONENT C1S; COMPLEMENT COMPONENT C1S INHIBITOR; COMPLEMENT COMPONENT C4; CREATININE; DANAZOL; ECALLANTIDE; FRESH FROZEN PLASMA; ICATIBANT; METHYLTESTOSTERONE; NORETHISTERONE; TRANEXAMIC ACID;

ABDOMINAL PAIN; ADULT; ANGIONEUROTIC EDEMA; APPENDECTOMY; CASE REPORT; COMORBIDITY; COMPLEMENT COMPONENT C1S INHIBITOR DEFICIENCY; COMPLEMENT DEFICIENCY; CREATININE BLOOD LEVEL; DIARRHEA; DISEASE COURSE; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DYSMENORRHEA; ENZYME LINKED IMMUNOSORBENT ASSAY; F12 GENE; FEMALE; FOLLOW UP; GASTROINTESTINAL SYMPTOM; GENE; GENE MUTATION; HUMAN; MALE; MYALGIA; NAUSEA; OPEN STUDY; OROPHARYNGEAL SWELLING; PATIENT ADVOCACY; PATIENT CARE; PREGNANCY; PRIORITY JOURNAL; QUALITY OF LIFE; RASH; RECURRENT DISEASE; REVIEW; SKIN SWELLING; SUFFOCATION; SWELLING; THROMBOSIS; VOMITING; YOUNG ADULT;

EID: 84973647623     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/bjh.14059     Document Type: Review

References (121)

1. Agostoni, A. & Cicardi, M. (1991) Contraindications to the use of ACE inhibitors in patients with C1 esterase inhibitor deficiency. American Journal of Medicine, 90, 278–278.
2. Agostoni, A. & Cicardi, M. (1992) Hereditary and acquired C1-inhibitor deficiency: biological and clinical characteristics in 235 patients. Medicine (Baltimore), 71, 206–215.
3. Agostoni, A., Cicardi, M., Cugno, M., Zingale, L.C., Gioffre, D. & Nussberger, J. (1999) Angioedema due to angiotensin-converting enzyme inhibitors. Immunopharmacology, 44, 21–25.
4. Baker, J.W., Craig, T.J., Riedl, M.A., Banerji, A., Fitts, D., Kalfus, I.N. & Uknis, M.E. (2013) Nanofiltered C1 esterase inhibitor (human) for hereditary angioedema attacks in pregnant women. Allergy and Asthma Proceedings, 34, 162–169.
5. Banerji, A. (2013) The burden of illness in patients with hereditary angioedema. Annals of Allergy, Asthma & Immunology, 111, 329–336.
6. Banerji, A., Busse, P., Christiansen, S.C., Li, H., Lumry, W., Davis-Lorton, M., Bernstein, J.A., Frank, M., Castaldo, A., Long, J.F., Zuraw, B.L. & Riedl, M. (2015) Current state of hereditary angioedema management: a patient survey. Allergy and Asthma Proceedings, 36, 213–217.
7. Bernstein, J.A., Manning, M.E., Li, H., White, M.V., Baker, J., Lumry, W.R., Davis-Lorton, M.A., Jacobson, K.W., Gower, R.G., Broom, C., Fitts, D. & Schranz, J. (2014) Escalating doses of C1 esterase inhibitor (CINRYZE) for prophylaxis in patients with hereditary angioedema. Journal of Allergy and Clinical Immunology. In Practice, 2, 77–84.
8. Berrettini, M., Lammle, B., White, T., Heeb, M.J., Schwarz, H.P., Zuraw, B., Curd, J. & Griffin, J.H. (1986) Detection of in vitro and in vivo cleavage of high molecular weight kininogen in human plasma by immunoblotting with monoclonal antibodies. Blood, 68, 455–462.
9. Binkley, K.E. (2010) Factor XII mutations, oestrogen-dependent inherited angioedema, and related conditions. Allergy, asthma, and clinical immunology, 6, 16.
10. Binkley, K.E. & Davis, A. 3rd (2000) Clinical, biochemical, and genetic characterization of a novel oestrogen- dependent inherited form of angioedema. Journal of Allergy and Clinical Immunology, 106, 546–550.
11. Bissler, J.J., Aulak, K.S., Donaldson, V.H., Rosen, F.S., Cicardi, M., Harrison, R.A. & Davis, A.E. 3rd (1997) Molecular defects in hereditary angioneurotic oedema. Proceedings of the Association of American Physicians, 109, 164–173.
12. Bjorkqvist, J., de Maat, S., Lewandrowski, U., Di Gennaro, A., Oschatz, C., Schonig, K., Nothen, M.M., Drouet, C., Braley, H., Nolte, M.W., Sickmann, A., Panousis, C., Maas, C. & Renne, T. (2015) Defective glycosylation of coagulation factor XII underlies hereditary angioedema type III. Journal of Clinical Investigation, 125, 3132–3146.
13. Blanch, A., Roche, O., Urrutia, I., Gamboa, P., Fontan, G. & Lopez-Trascasa, M. (2006) First case of homozygous C1 inhibitor deficiency. The Journal of allergy and clinical immunology, 118, 1330–1335.
14. Boccon-Gibod, I. & Bouillet, L. (2012) Safety and efficacy of icatibant self-administration for acute hereditary angioedema. Clinical and experimental immunology, 168, 303–307.
15. Bork, K. (2010) Diagnosis and treatment of hereditary angioedema with normal C1 inhibitor. Allergy, asthma, and clinical immunology, 6, 15.
16. Bork, K. (2013) Hereditary angioedema with normal c1 inhibitor. Immunology and Allergy Clinics of North America, 33, 457–470.
17. Bork, K. & Barnstedt, S.E. (2003) Laryngeal oedema and death from asphyxiation after tooth extraction in four patients with hereditary angioedema. Journal of the American Dental Association, 134, 1088–1094.
18. Bork, K. & Dewald, G. (2004) Hereditary angioedema type III, angioedema associated with angiotensin II receptor antagonists, and female sex. American Journal of Medicine, 116, 644–645.
19. Bork, K., Barnstedt, S.E., Koch, P. & Traupe, H. (2000) Hereditary angioedema with normal C1-inhibitor activity in women. Lancet, 356, 213–217.
20. Bork, K., Meng, G., Staubach, P. & Hardt, J. (2006a) Hereditary angioedema: new findings concerning symptoms, affected organs, and course. American Journal of Medicine, 119, 267–274.
21. Bork, K., Gul, D. & Dewald, G. (2006b) Hereditary angio-oedema with normal C1 inhibitor in a family with affected women and men. British Journal of Dermatology, 154, 542–545.
22. Bork, K., Bygum, A. & Hardt, J. (2008) Benefits and risks of danazol in hereditary angioedema: a long-term survey of 118 patients. Annals of Allergy, Asthma & Immunology, 100, 153–161.
23. Bork, K., Wulff, K., Hardt, J., Witzke, G. & Staubach, P. (2009) Hereditary angioedema caused by missense mutations in the factor XII gene: clinical features, trigger factors, and therapy. Journal of Allergy and Clinical Immunology, 124, 129–134.
24. Bork, K., Hardt, J., Staubach-Renz, P. & Witzke, G. (2011) Risk of laryngeal oedema and facial swellings after tooth extraction in patients with hereditary angioedema with and without prophylaxis with C1 inhibitor concentrate: a retrospective study. Oral surgery, oral medicine, oral pathology, oral radiology, and endodontics, 112, 58–64.
25. Bork, K., Hardt, J. & Witzke, G. (2012) Fatal laryngeal attacks and mortality in hereditary angioedema due to C1-INH deficiency. Journal of Allergy and Clinical Immunology, 130, 692–697.
26. Bork, K., Wulff, K., Witzke, G. & Hardt, J. (2015) Hereditary angioedema with normal C1-INH with versus without specific F12 gene mutations. Allergy, 70, 1004–1012.
27. Bouillet, L. & Gompel, A. (2013) Hereditary angioedema in women: specific challenges. Immunology and Allergy Clinics of North America, 33, 505–511.
28. Bouillet, L., Longhurst, H., Boccon-Gibod, I., Bork, K., Bucher, C., Bygum, A., Caballero, T., Drouet, C., Farkas, H., Massot, C., Nielsen, E.W., Ponard, D. & Cicardi, M. (2008) Disease expression in women with hereditary angioedema. American Journal of Obstetrics & Gynecology, 199, e481–e484.
29. Bouillet, L., Mannic, T., Arboleas, M., Subileau, M., Massot, C., Drouet, C., Huber, P. & Vilgrain, I. (2011) Hereditary angioedema: key role for kallikrein and bradykinin in vascular endothelial-cadherin cleavage and oedema formation. The Journal of allergy and clinical immunology, 128, 232–234.
30. Bouillet, L., Launay, D., Fain, O., Boccon-Gibod, I., Laurent, J., Martin, L., Montauban, V., Finck, K., Bouee, S., Gompel, A., Kanny, G. & French National Reference Center for Hereditary, A(2013) Hereditary angioedema with C1 inhibitor deficiency: clinical presentation and quality of life of 193 French patients. Annals of Allergy, Asthma & Immunology, 111, 290–294.
31. Bowen, T., Cicardi, M., Bork, K., Zuraw, B., Frank, M., Ritchie, B., Farkas, H., Varga, L., Zingale, L.C., Binkley, K., Wagner, E., Adomaitis, P., Brosz, K., Burnham, J., Warrington, R., Kalicinsky, C., Mace, S., McCusker, C., Schellenberg, R., Celeste, L., Hebert, J., Valentine, K., Poon, M.C., Serushago, B., Neurath, D., Yang, W., Lacuesta, G., Issekutz, A., Hamed, A., Kamra, P., Dean, J., Kanani, A., Stark, D., Rivard, G.E., Leith, E., Tsai, E., Waserman, S., Keith, P.K., Page, D., Marchesin, S., Longhurst, H.J., Kreuz, W., Rusicke, E., Martinez-Saguer, I., Aygoren-Pursun, E., Harmat, G., Fust, G., Li, H., Bouillet, L., Caballero, T., Moldovan, D., Spath, P.J., Smith-Foltz, S., Nagy, I., Nielsen, E.W., Bucher, C., Nordenfelt, P. & Xiang, Z.Y. (2008) Hereditary angiodema: a current state-of-the-art review, VII: canadian Hungarian 2007 International Consensus Algorithm for the Diagnosis, Therapy, and Management of Hereditary Angioedema. Annals of Allergy, Asthma & Immunology, 100, S30–S40.
32. Bowen, T., Cicardi, M., Farkas, H., Bork, K., Longhurst, H.J., Zuraw, B., Aygoeren-Pursun, E., Craig, T., Binkley, K., Hebert, J., Ritchie, B., Bouillet, L., Betschel, S., Cogar, D., Dean, J., Devaraj, R., Hamed, A., Kamra, P., Keith, P.K., Lacuesta, G., Leith, E., Lyons, H., Mace, S., Mako, B., Neurath, D., Poon, M.C., Rivard, G.E., Schellenberg, R., Rowan, D., Rowe, A., Stark, D., Sur, S., Tsai, E., Warrington, R., Waserman, S., Ameratunga, R., Bernstein, J., Bjorkander, J., Brosz, K., Brosz, J., Bygum, A., Caballero, T., Frank, M., Fust, G., Harmat, G., Kanani, A., Kreuz, W., Levi, M., Li, H., Martinez-Saguer, I., Moldovan, D., Nagy, I., Nielsen, E.W., Nordenfelt, P., Reshef, A., Rusicke, E., Smith-Foltz, S., Spath, P., Varga, L. & Xiang, Z.Y. (2010) 2010 International consensus algorithm for the diagnosis, therapy and management of hereditary angioedema. Allergy, asthma, and clinical immunology, 6, 24.
33. Brown, N.J., Snowden, M. & Griffin, M.R. (1997) Recurrent angiotensin-converting enzyme inhibitor–associated angioedema. JAMA, 278, 232–233.
34. Busse, P., Bygum, A., Edelman, J., Lumry, W., Machnig, T., Martinez-Saguer, I. & Rojavin, M. (2015) Safety of C1-esterase inhibitor in acute and prophylactic therapy of hereditary angioedema: findings from the ongoing international Berinert patient registry. Journal of Allergy and Clinical Immunology. In Practice, 3, 213–219.
35. Caballero, T., Farkas, H., Bouillet, L., Bowen, T., Gompel, A., Fagerberg, C., Bjorkander, J., Bork, K., Bygum, A., Cicardi, M., de Carolis, C., Frank, M., Gooi, J., Longhurst, H., Martinez-Saguer, I., Nielsen, E.W., Obtulowicz, K., Perricone, R. & Prior, N. (2012) International consensus and practical guidelines on the gynecologic and obstetric management of female patients with hereditary angioedema caused by C1 inhibitor deficiency. Journal of Allergy and Clinical Immunology, 129, 308–320.
36. Caballero, T., Aygoren-Pursun, E., Bygum, A., Beusterien, K., Hautamaki, E., Sisic, Z., Wait, S. & Boysen, H.B. (2014) The humanistic burden of hereditary angioedema: results from the Burden of Illness Study in Europe. Allergy and Asthma Proceedings, 35, 47–53.
37. Christiansen, S.C., Davis, D.K., Castaldo, A.J. & Zuraw, B.L. (2015a) Pediatric Hereditary Angioedema: onset, Diagnostic Delay, and Disease Severity. Clin Pediatr (Phila), 2015 Nov 18. pii: 0009922815616886. [Epub ahead of print] doi: 10.1177/0009922815616886
38. Christiansen, S.C., Bygum, A., Banerji, A., Busse, P., Li, H., Lumry, W., Davis-Lorton, M., Bernstein, J.A., Frank, M.M., Castaldo, A., Long, J.F., Riedl, M. & Zuraw, B.L. (2015b) Before and after, the impact of available on-demand treatment for HAE. Allergy and Asthma Proceedings, 36, 145–150.
39. Cicardi, M., Banerji, A., Bracho, F., Malbran, A., Rosenkranz, B., Riedl, M., Bork, K., Lumry, W., Aberer, W., Bier, H., Bas, M., Greve, J., Hoffmann, T.K., Farkas, H., Reshef, A., Ritchie, B., Yang, W., Grabbe, J., Kivity, S., Kreuz, W., Levy, R.J., Luger, T., Obtulowicz, K., Schmid-Grendelmeier, P., Bull, C., Sitkauskiene, B., Smith, W.B., Toubi, E., Werner, S., Anne, S., Bjorkander, J., Bouillet, L., Cillari, E., Hurewitz, D., Jacobson, K.W., Katelaris, C.H., Maurer, M., Merk, H., Bernstein, J.A., Feighery, C., Floccard, B., Gleich, G., Hebert, J., Kaatz, M., Keith, P., Kirkpatrick, C.H., Langton, D., Martin, L., Pichler, C., Resnick, D., Wombolt, D., Fernandez Romero, D.S., Zanichelli, A., Arcoleo, F., Knolle, J., Kravec, I., Dong, L., Zimmermann, J., Rosen, K. & Fan, W.T. (2010a) Icatibant, a new bradykinin-receptor antagonist, in hereditary angioedema. New England Journal of Medicine, 363, 532–541.
40. Cicardi, M., Levy, R.J., McNeil, D.L., Li, H.H., Sheffer, A.L., Campion, M., Horn, P.T. & Pullman, W.E. (2010b) Ecallantide for the treatment of acute attacks in hereditary angioedema. New England Journal of Medicine, 363, 523–531.
41. Cicardi, M., Bork, K., Caballero, T., Craig, T., Li, H.H., Longhurst, H., Reshef, A. & Zuraw, B. (2012) Evidence-based recommendations for the therapeutic management of angioedema owing to hereditary C1 inhibitor deficiency: consensus report of an International Working Group. Allergy, 67, 147–157.
42. Cichon, S., Martin, L., Hennies, H.C., Muller, F., Van Driessche, K., Karpushova, A., Stevens, W., Colombo, R., Renne, T., Drouet, C., Bork, K. & Nothen, M.M. (2006) Increased activity of coagulation factor XII (Hageman factor) causes hereditary angioedema type III. American Journal of Human Genetics, 79, 1098–1104.
43. Craig, T.J., Levy, R.J., Wasserman, R.L., Bewtra, A.K., Hurewitz, D., Obtulowicz, K., Reshef, A., Ritchie, B., Moldovan, D., Shirov, T., Grivcheva-Panovska, V., Kiessling, P.C., Keinecke, H.O. & Bernstein, J.A. (2009) Efficacy of human C1 esterase inhibitor concentrate compared with placebo in acute hereditary angioedema attacks. Journal of Allergy and Clinical Immunology, 124, 801–808.
44. Craig, T., Pursun, E.A., Bork, K., Bowen, T., Boysen, H., Farkas, H., Grumach, A., Katelaris, C.H., Lockey, R., Longhurst, H., Lumry, W., Magerl, M., Martinez-Saguer, I., Ritchie, B., Nast, A., Pawankar, R., Zuraw, B. & Maurer, M. (2012) WAO Guideline for the Management of Hereditary Angioedema. The World Allergy Organization journal, 5, 182–199.
45. Craig, T.J., Li, H.H., Riedl, M., Bernstein, J.A., Lumry, W.R., MacGinnitie, A.J., Stolz, L.E., Biedenkapp, J. & Chyung, Y. (2015) Characterization of anaphylaxis after ecallantide treatment of hereditary angioedema attacks. Journal of Allergy and Clinical Immunology. In Practice, 3, e204.
46. Cronin, J.A. & Maples, K.M. (2012) Treatment of an acute attack of type III hereditary angioedema with ecallantide. Annals of Allergy, Asthma & Immunology, 108, 61–62.
47. Crowther, M., Bauer, K.A. & Kaplan, A.P. (2014) The thrombogenicity of C1 esterase inhibitor (human): review of the evidence. Allergy and Asthma Proceedings, 35, 444–453.
48. Czaller, I., Visy, B., Csuka, D., Fust, G., Toth, F. & Farkas, H. (2010) The natural history of hereditary angioedema and the impact of treatment with human C1-inhibitor concentrate during pregnancy: a long-term survey. European Journal of Obstetrics, Gynecology, and Reproductive Biology, 152, 44–49.
49. Davis, A.E. III (1988) C1 inhibitor and hereditary angioneurotic oedema. Annual Review of Immunology, 6, 595–628.
50. Davis, A.E. 3rd (2006) Mechanism of angioedema in first complement component inhibitor deficiency. Immunology and Allergy Clinics of North America, 26, 633–651.
51. Davis, A.E. III, Aulak, K., Parad, R.B., Stecklein, H.P., Eldering, E., Hack, C.E., Kramer, J., Strunk, R.C., Bissler, J. & Rosen, F.S. (1992) C1 inhibitor hinge region mutations produce dysfunction by different mechanisms. Nature Genetics, 1, 354–358.
52. Defendi, F., Charignon, D., Ghannam, A., Baroso, R., Csopaki, F., Allegret-Cadet, M., Ponard, D., Favier, B., Cichon, S., Nicolie, B., Fain, O., Martin, L. & Drouet, C. & National Reference Centre for Angioedema, C. (2013) Enzymatic assays for the diagnosis of bradykinin-dependent angioedema. PLoS ONE, 8, e70140.
53. Dewald, G. & Bork, K. (2006) Missense mutations in the coagulation factor XII (Hageman factor) gene in hereditary angioedema with normal C1 inhibitor. Biochemical and Biophysical Research Communications, 343, 1286–1289.
54. Donaldson, V.H. & Evans, R.R. (1963) A biochemical abnormality in hereditary angioneurotic edema: absence of serum inhibitor of C'1- esterase. American Journal of Medicine, 35, 37–44.
55. Duan, Q.L., Binkley, K. & Rouleau, G.A. (2009) Genetic analysis of Factor XII and bradykinin catabolic enzymes in a family with estrogen-dependent inherited angioedema. Journal of Allergy and Clinical Immunology, 123, 906–910.
56. Ernst, S.C., Circolo, A., Davis, A.E. 3rd, Gheesling-Mullis, K., Fliesler, M. & Strunk, R.C. (1996) Impaired production of both normal and mutant C1 inhibitor proteins in type I hereditary angioedema with a duplication in exon 8. Journal of Immunology, 157, 405–410.
57. Farkas, H., Csuka, D., Veszeli, N., Zotter, Z., Szabo, E. & Varga, L. (2014) Home treatment of attacks with conestat alfa in hereditary angioedema due to C1-inhibitor deficiency. Allergy and Asthma Proceedings, 35, 255–259.
58. Farsetti, A., Misiti, S., Citarella, F., Felici, A., Andreoli, M., Fantoni, A., Sacchi, A. & Pontecorvi, A. (1995) Molecular basis of estrogen regulation of Hageman factor XII gene expression. Endocrinology, 136, 5076–5083.
59. Fouche, A.S., Saunders, E.F. & Craig, T. (2014) Depression and anxiety in patients with hereditary angioedema. Annals of Allergy, Asthma & Immunology, 112, 371–375.
60. Frank, M.M., Gelfand, J.A. & Atkinson, J.P. (1976) Hereditary angioedema: the clinical syndrome and its management. Annals of Internal Medicine, 84, 586–593.
61. Gandhi, P.K., Gentry, W.M. & Bottorff, M.B. (2012) Thrombotic events associated with C1 esterase inhibitor products in patients with hereditary angioedema: investigation from the United States Food and Drug Administration adverse event reporting system database. Pharmacotherapy, 32, 902–909.
62. Gelfand, J.A., Sherins, R.J., Alling, D.W. & Frank, M.M. (1976) Treatment of hereditary angioedema with danazol. New England Journal of Medicine, 295, 1444–1448.
63. Hack, C.E., Relan, A., Baboeram, A., Oortwijn, B., Versteeg, S., van Ree, R. & Pijpstra, R. (2013) Immunosafety of recombinant human C1-inhibitor in hereditary angioedema: evaluation of ige antibodies. Clinical Drug Investigation, 33, 275–281.
64. Herrmann, G., Schneider, L., Krieg, T., Hunzelmann, N. & Scharffetter-Kochanek, K. (2004) Efficacy of danazol treatment in a patient with the new variant of hereditary angio-oedema (HAE III). British Journal of Dermatology, 150, 157–158.
65. Hofman, Z.L., Relan, A. & Hack, C.E. (2016) Hereditary Angioedema Attacks: local Swelling at Multiple Sites. Clinical Reviews in Allergy and Immunology, 50, 34–40.
66. Israili, Z.H. & Hall, W.D. (1992) Cough and angioneurotic edema associated with angiotensin-converting enzyme inhibitor therapy. A review of the literature and pathophysiology. Annals of Internal Medicine, 117, 234–242.
67. Joseph, K., Tholanikunnel, B.G., Wolf, B., Bork, K. & Kaplan, A.P. (2015) Deficiency of plasminogen activator inhibitor 2 in plasma of patients with hereditary angioedema with normal C1 inhibitor levels. Journal of Allergy and Clinical Immunology. 2015 Sep 26. pii: S0091-6749(15)01104-5. doi: 10.1016/j.jaci.2015.07.041 [Epub ahead of print]
68. Kalaria, S. & Craig, T. (2013) Assessment of hereditary angioedema treatment risks. Allergy and Asthma Proceedings, 34, 519–522.
69. Kaplan, A.P. & Austen, K.F. (1972) The fibrinolytic pathway of human plasma. Isolation and characterization of the plasminogen proactivator. Journal of Experimental Medicine, 136, 1378–1393.
70. Kramer, J., Rosen, F.S., Colten, H.R., Rajczy, K. & Strunk, R.C. (1993) Transinhibition of C1 inhibitor synthesis in type I hereditary angioneurotic edema. Journal of Clinical Investigation, 91, 1258–1262.
71. Kuhlen, J.L. & Banerji, A. (2015) Hereditary angioedema: special consideration in children, women of childbearing age, and the elderly. Allergy and Asthma Proceedings, 36, 425–432.
72. Lachmann, P.J. & Rosen, F.S. (1984) The catabolism of C1-inhibitor and the pathogenesis of hereditary angio-edema. Acta Path Microbiol Scand, 92, 35–39.
73. Lang, D.M., Aberer, W., Bernstein, J.A., Chng, H.H., Grumach, A.S., Hide, M., Maurer, M., Weber, R. & Zuraw, B. (2012) International consensus on hereditary and acquired angioedema. Annals of allergy asthma immunology, 109, 395–402.
74. Li, H.H., Busse, P., Lumry, W.R., Frazer-Abel, A., Levy, H., Steele, T., Dayno, J. & Riedl, M. (2015) Comparison of chromogenic and ELISA functional C1 inhibitor tests in diagnosing hereditary angioedema. Journal of Allergy and Clinical Immunology. In Practice, 3, 200–205.
75. Lindoff, C., Rybo, G. & Astedt, B. (1993) Treatment with tranexamic acid during pregnancy, and the risk of thrombo-embolic complications. Thrombosis and Haemostasis, 70, 238–240.
76. Longhurst, H. & Cicardi, M. (2012) Hereditary angio-oedema. Lancet, 379, 474–481.
77. Lopez-Lera, A., Favier, B., de la Cruz, R.M., Garrido, S., Drouet, C. & Lopez-Trascasa, M. (2010) A new case of homozygous C1-inhibitor deficiency suggests a role for Arg378 in the control of kinin pathway activation. Journal of Allergy and Clinical Immunology, 126, e1303.
78. Lumry, W.R., Castaldo, A.J., Vernon, M.K., Blaustein, M.B., Wilson, D.A. & Horn, P.T. (2010) The humanistic burden of hereditary angioedema: impact on health-related quality of life, productivity, and depression. Allergy and asthma proceedings, 31, 407–414.
79. Lumry, W.R., Bernstein, J.A., Li, H.H., MacGinnitie, A.J., Riedl, M., Soteres, D.F., Craig, T.J., Campion, M., Iarrobino, R., Stolz, L.E. & Pullman, W.E. (2013a) Efficacy and safety of ecallantide in treatment of recurrent attacks of hereditary angioedema: open-label continuation study. Allergy and Asthma Proceedings, 34, 155–161.
80. Lumry, W., Manning, M.E., Hurewitz, D.S., Davis-Lorton, M., Fitts, D., Kalfus, I.N. & Uknis, M.E. (2013b) Nanofiltered C1-esterase inhibitor for the acute management and prevention of hereditary angioedema attacks due to C1-inhibitor deficiency in children. Journal of Pediatrics, 162, e1011–e1012.
81. Lumry, W.R., Miller, D.P., Newcomer, S., Fitts, D. & Dayno, J. (2014) Quality of life in patients with hereditary angioedema receiving therapy for routine prevention of attacks. Allergy and Asthma Proceedings, 35, 371–376.
82. MacGinnitie, A.J., Davis-Lorton, M., Stolz, L.E. & Tachdjian, R. (2013) Use of ecallantide in pediatric hereditary angioedema. Pediatrics, 132, e490–e497.
83. Mansi, M., Zanichelli, A., Coerezza, A., Suffritti, C., Wu, M.A., Vacchini, R., Stieber, C., Cichon, S. & Cicardi, M. (2015) Presentation, diagnosis and treatment of angioedema without wheals: a retrospective analysis of a cohort of 1058 patients. Journal of Internal Medicine, 277, 585–593.
84. Marcos, C., Lopez Lera, A., Varela, S., Linares, T., Alvarez-Eire, M.G. & Lopez-Trascasa, M. (2012) Clinical, biochemical, and genetic characterization of type III hereditary angioedema in 13 Northwest Spanish families. Annals of Allergy, Asthma & Immunology, 109, e192.
85. Martinez-Saguer, I., Rusicke, E., Aygoren-Pursun, E., Heller, C., Klingebiel, T. & Kreuz, W. (2010) Characterization of acute hereditary angioedema attacks during pregnancy and breast-feeding and their treatment with C1 inhibitor concentrate. American journal of obstetrics and gynecology, 203, e131–e137.
86. Milton, J.L. (1876) On giant urticaria. Edinburgh Medical Journal, 22, 513–526.
87. Miranda, A.R., Ue, A.P., Sabbag, D.V., Furlani Wde, J., Souza, P.K. & Rotta, O. (2013) Hereditary angioedema type III (estrogen-dependent) report of three cases and literature review. Anais Brasileiros de Dermatologia, 88, 578–584.
88. Moellman, J.J., Bernstein, J.A., Lindsell, C., Banerji, A., Busse, P.J., Camargo, C.A. Jr, Collins, S.P., Craig, T.J., Lumry, W.R., Nowak, R., Pines, J.M., Raja, A.S., Riedl, M., Ward, M.J., Zuraw, B.L., Diercks, D., Hiestand, B., Campbell, R.L., Schneider, S. & Sinert, R. (2014) A consensus parameter for the evaluation and management of angioedema in the emergency department. Academic Emergency Medicine, 21, 469–484.
89. Nussberger, J., Cugno, M., Cicardi, M. & Agostoni, A. (1999) Local bradykinin generation in hereditary angioedema. Journal of Allergy and Clinical Immunology, 104, 1321–1322.
90. Nzeako, U.C., Frigas, E. & Tremaine, W.J. (2001) Hereditary angioedema: a broad review for clinicians. Archives of Internal Medicine, 161, 2417–2429.
91. Osler, W. (1888) Hereditary Angio-Neurotic Oedema. The American Journal of the Medical Sciences, 95, 362–367.
92. Papamanthos, M., Matiakis, A., Tsirevelou, P., Kolokotronis, A. & Skoulakis, H. (2010) Hereditary angioedema: three cases report, members of the same family. Journal of Oral & Maxillofacial Research, 1, e9.
93. Pappalardo, E., Cicardi, M., Duponchel, C., Carugati, A., Choquet, S., Agostoni, A. & Tosi, M. (2000) Frequent de novo mutations and exon deletions in the C1inhibitor gene of patients with angioedema. Journal of Allergy and Clinical Immunology, 106, 1147–1154.
94. Quastel, M., Harrison, R., Cicardi, M., Alper, C.A. & Rosen, F.S. (1983) Behavior in vivo of normal and dysfunctional C1 inhibitor in normal subjects and patients with hereditary angioneurotic edema. Journal of Clinical Investigation, 71, 1041–1046.
95. Quincke, H. (1882) Über akutes umschriebenes Hautödem. Monatsh Prakt Dermatol, 1, 129–131.
96. Roche, O., Blanch, A., Caballero, T., Sastre, N., Callejo, D. & Lopez-Trascasa, M. (2005) Hereditary angioedema due to C1 inhibitor deficiency: patient registry and approach to the prevalence in Spain. Annals of Allergy, Asthma & Immunology, 94, 498–503.
97. Rosen, F.S., Charache, P., Pensky, J. & Donaldson, V.H. (1965) Hereditary angioneurotic edema: two genetic variants. Science, 148, 957–958.
98. Rousset-Jablonski, C., Thalabard, J.C. & Gompel, A. (2009) Tamoxifen contraindicated in women with hereditary angioedema? Annals of Oncology, 20, 1281–1282.
99. Saule, C., Boccon-Gibod, I., Fain, O., Kanny, G., Plu-Bureau, G., Martin, L., Launay, D., Bouillet, L. & Gompel, A. (2013) Benefits of progestin contraception in non-allergic angioedema. Clinical & Experimental Allergy, 43, 475–482.
100. Schneider, L., Hurewitz, D., Wasserman, R., Obtulowicz, K., Machnig, T., Moldovan, D., Reshef, A. & Craig, T.J. (2013) C1-INH concentrate for treatment of acute hereditary angioedema: a pediatric cohort from the I.M.P.A.C.T. studies. Pediatric Allergy and Immunology, 24, 54–60.
101. Schurmann, D., Herzog, E., Raquet, E., Nolte, M.W., May, F., Muller-Cohrs, J., Bjorkqvist, J., Dickneite, G. & Pragst, I. (2014) C1-esterase inhibitor treatment: preclinical safety aspects on the potential prothrombotic risk. Thrombosis and Haemostasis, 112, 960–971.
102. Serrano, C., Guilarte, M., Tella, R., Dalmau, G., Bartra, J., Gaig, P., Cerda, M., Cardona, V. & Valero, A. (2008) Oestrogen-dependent hereditary angio-oedema with normal C1 inhibitor: description of six new cases and review of pathogenic mechanisms and treatment. Allergy, 63, 735–741.
103. Sheffer, A.L., Fearon, D.T. & Austen, K.F. (1977) Methyltestosterone therapy in hereditary angioedema. Annals of Internal Medicine, 86, 306–308.
104. Tourangeau, L.M., Castaldo, A.J., Davis, D.K., Koziol, J., Christiansen, S.C. & Zuraw, B.L. (2012) Safety and efficacy of physician-supervised self-managed c1 inhibitor replacement therapy. International Archives of Allergy and Immunology, 157, 417–424.
105. Verpy, E., Biasotto, M., Brai, M., Misiano, G., Meo, T. & Tosi, M. (1996) Exhaustive mutation scanning by fluorescence-assisted mismatch analysis discloses new genotype-phenotype correlations in angiodema [see comments]. American Journal of Human Genetics, 59, 308–319.
106. Vogetseder, W. & Tilg, H. (2011) Abdominal pain beyond IBS. Hereditary angioedema (HAE type III). Gastroenterology, 140, 371.
107. Wagenaar-Bos, I.G., Drouet, C., Aygoren-Pursun, E., Bork, K., Bucher, C., Bygum, A., Farkas, H., Fust, G., Gregorek, H., Hack, C.E., Hickey, A., Joller-Jemelka, H.I., Kapusta, M., Kreuz, W., Longhurst, H., Lopez-Trascasa, M., Madalinski, K., Naskalski, J., Nieuwenhuys, E., Ponard, D., Truedsson, L., Varga, L., Nielsen, E.W., Wagner, E., Zingale, L., Cicardi, M. & van Ham, S.M. (2008) Functional C1-inhibitor diagnostics in hereditary angioedema: assay evaluation and recommendations. Journal of Immunological Methods, 338, 14–20.
108. Wahn, V., Aberer, W., Eberl, W., Fasshauer, M., Kuhne, T., Kurnik, K., Magerl, M., Meyer-Olson, D., Martinez-Saguer, I., Spath, P., Staubach-Renz, P. & Kreuz, W. (2012) Hereditary angioedema (HAE) in children and adolescents–a consensus on therapeutic strategies. European Journal of Pediatrics, 171, 1339–1348.
109. Winnewisser, J., Rossi, M., Spath, P. & Burgi, H. (1997) Type I hereditary angio-oedema. Variability of clinical presentation and course within two large kindreds. Journal of Internal Medicine, 241, 39–46.
110. Yoo, S.M. & Khan, D.A. (2013) Implantable venous access device associated complications in patients with hereditary angioedema. The Journal of Allergy and Clinical Immunology. In Practice, 1, 524–525.
111. Zanichelli, A., Vacchini, R., Badini, M., Penna, V. & Cicardi, M. (2011) Standard care impact on angioedema because of hereditary C1 inhibitor deficiency: a 21-month prospective study in a cohort of 103 patients. Allergy, 66, 192–196.
112. Zotter, Z., Csuka, D., Szabo, E., Czaller, I., Nebenfuhrer, Z., Temesszentandrasi, G., Fust, G., Varga, L. & Farkas, H. (2014) The influence of trigger factors on hereditary angioedema due to C1-inhibitor deficiency. Orphanet Journal of Rare Diseases, 9, 44.
113. Zuraw, B.L. (2008) Clinical practice. Hereditary angioedema. New England Journal of Medicine, 359, 1027–1036.
114. Zuraw, B.L. & Curd, J.G. (1986) Demonstration of modified inactive first component of complement (C1) inhibitor in the plasmas of C1 inhibitor-deficient patients. Journal of Clinical Investigation, 78, 567–575.
115. Zuraw, B.L. & Herschbach, J. (2000) Detection of C1 inhibitor mutations in patients with hereditary angioedema. Journal of Allergy and Clinical Immunology, 105, 541–546.
116. Zuraw, B.L. & Kalfus, I. (2012) Safety and efficacy of prophylactic nanofiltered C1-inhibitor in hereditary angioedema. American Journal of Medicine, 125, e931–e937.
117. Zuraw, B., Cicardi, M., Levy, R.J., Nuijens, J.H., Relan, A., Visscher, S., Haase, G., Kaufman, L. & Hack, C.E. (2010a) Recombinant human C1-inhibitor for the treatment of acute angioedema attacks in patients with hereditary angioedema. Journal of Allergy and Clinical Immunology, 126, e814.
118. Zuraw, B.L., Busse, P.J., White, M., Jacobs, J., Lumry, W., Baker, J., Craig, T., Grant, J.A., Hurewitz, D., Bielory, L., Cartwright, W.E., Koleilat, M., Ryan, W., Schaefer, O., Manning, M., Patel, P., Bernstein, J.A., Friedman, R.A., Wilkinson, R., Tanner, D., Kohler, G., Gunther, G., Levy, R., McClellan, J., Redhead, J., Guss, D., Heyman, E., Blumenstein, B.A., Kalfus, I. & Frank, M.M. (2010b) Nanofiltered C1 inhibitor concentrate for treatment of hereditary angioedema. New England Journal of Medicine, 363, 513–522.
119. Zuraw, B.L., Bork, K., Binkley, K.E., Banerji, A., Christiansen, S.C., Castaldo, A., Kaplan, A., Riedl, M., Kirkpatrick, C., Magerl, M., Drouet, C. & Cicardi, M. (2012) Hereditary angioedema with normal C1 inhibitor function: consensus of an international expert panel. Allergy and asthma proceedings, 33, S145–S156.
120. Zuraw, B.L., Banerji, A., Bernstein, J.A., Busse, P.J., Christiansen, S.C., Davis-Lorton, M., Frank, M.M., Li, H.H., Lumry, W.R. & Riedl, M. (2013a) US Hereditary Angioedema Association Medical Advisory Board 2013 Recommendations for the Management of Hereditary Angioedema Due to C1 Inhibitor Deficiency. Journal of Allergy and Clinical Immunology. In Practice, 1, 458–467.
121. Zuraw, B.L., Bernstein, J.A., Lang, D.M., Craig, T., Dreyfus, D., Hsieh, F., Khan, D., Sheikh, J., Weldon, D., Bernstein, D.I., Blessing-Moore, J., Cox, L., Nicklas, R.A., Oppenheimer, J., Portnoy, J.M., Randolph, C.R., Schuller, D.E., Spector, S.L., Tilles, S.A. & Wallace, D. (2013b) A focused parameter update: hereditary angioedema, acquired C1 inhibitor deficiency, and angiotensin-converting enzyme inhibitor-associated angioedema. The Journal of allergy and clinical immunology, 131, e1425.